CSI Market
Sign In | Register

Carisma Therapeutics Inc (CARM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CARM Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Carisma Therapeutics Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income25.68
Depreciation & amortization0.66
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-44.98
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets3.11
Share-based Compensation1.36
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Write Off Of Deferred Debt Issuance Cost0.21
Liabilities Assumed-
Increase Decrease Of Prepaid Expenses Noncurrent-
Operating Lease Right Of Use Asset Amortization Expense1.27
Embedded Derivative Gain Loss On Embedded Derivative Net-
Accretion On Marketable Securities-
Noncash Interest Expense0.03
Increase Decrease In Operating Lease Liability-1.63
Income taxes0.00
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable3.09
Increase (Decrease) in Accrued Liabilities-6.36
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.52
Other Working Capital0.06
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.93
Discontinued operations0.00
Net Cash flow from Operating Activities-14.06
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.69
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payments For Proceeds From Marketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.69
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-17.91
Proceeds From Issuance of Common Stock and Warrants-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents17.91
Finance Lease Principal Payments-0.24
Proceeds From Failed Sale Leaseback Transaction-
Payment Of Finance Liability Failed Sale Leaseback Transaction-1.52
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.76
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-13.38
Total Cash Flow-15.13
4 historic quarters locked

Sign in to unlock the full Carisma Therapeutics Inc cash flow history.

Sign In Create Free Account

About Carisma Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-25-110444

Figures are derived from filed reports and may be restated. Historical data is subject to revision.